Big news hits traders as APRU confirms its entry into the $1.2 billion hemp industry with CannaRush energy chews. Big rally immediately follows the big announcement
Notes from Crag-Hallum Mr.Benello below.
TearLab (NASDAQ:TEAR; TSX:TLB) has reported interim results of a multi-center dry eye disease (DED) prevalence study being carried out in the UK at four National Health Service (NHS) hospitals. The study compared the effectiveness of the TearLab Osmolarity test to other traditional methods of diagnosing DED.
nhsConducted under the auspices of the UK’s National Institute of Health Research, the study began in March and its interim phase was completed in June.
The interim clinical trial results showed that osmolarity had the highest agreement with the International Dry Eye Workshop (DEWS) findings, which is a composite score based on several tests, and that “traditional” tests like Staining and TBUT do not correlate well with the presence of the disease.
“The interim results of this study could have far reaching consequences for the evaluation, diagnosis and management of dry eye disease in the UK,” lead investigator and consultant ophthalmologist, Francesca Harman, from Hillingdon Hospital, said in a statement.
Craig-Hallum analyst, Bill Bonello, wrote in a note to clients, “We believe that the results of this study are extremely positive for TEAR, increasing the potential that the TearLab osmolarity test will eventually be adopted by the UK’s National Health Service.”
Mr. Benello noted that the interim results showed that of all the tests used, osmolarity had the highest correlation to actual disease.
He figures that the implication from these results is that implementation of TearLab Osmolarity testing could potentially improve diagnosis, and reduce cost, within the NHS.
“The current practice in the NHS is for symptomatic patients to visit a general practitioner, who would then refer that patient on to an ophthalmologist at a cost of approximately $60 per visit,” he added. “Even then, the tests being performed by the ophthalmologist are genera
Thanks for posting. This research note is what the company press release should have looked like. The PR was gibberish. Notice that there was even lower than average volume on the day and the stock couldn't gain any steam. We are due for a pop above 4 but need a catalyst.
This morning, TEAR announced interim results of a multi-center dry eye disease (DED) prevalence study being carried out at four hospitals in the U.K.
We believe that the results of this study are extremely positive for TEAR, increasing the potential that the TearLab osmolarity test will eventually be adopted by the UK’s National Health Service (NHS).
• The study compared the effectiveness of the TearLab osmolarity test as compared to other traditional methods of diagnosing dry eye disease (DED).
• The interim results showed that of all the tests used, osmolarity had the highest correlation to actual disease
• The study also found that ‘traditional’ methods of detecting dry eye do not work well. Of particular note is the fact that ~20% of patients with significant symptoms had no other sign of dry eye except for hyperosmolarity and the fact that without an osmolarity test doctors were only able to diagnose 34 of these symptomatic patients (~28%) with dry eye disease.
• The implication from these results is that implementation of osmolarity testing could potentially improve diagnosis, and reduce cost, within the NHS. The current practice in the NHS is for symptomatic patients to visit a general practitioner, who would then refer that patient on to an ophthalmologist at a cost of approximately $60 per visit. Even then, the tests being performed by the ophthalmologist are generally ineffective. An alternative practice might be to have the GP’s accurately diagnose DED using the TEARLAB test and avoiding the ophthalmology referral altogether.
CTLE ready to deploy Technosoil technology in the United States after signing massive JV deal with Mexican nanotech giant, POLEC INDUSTRIAS S de RL de CV (POLEC(R))
"The right way to market the company is to under promise and over delivery." They did not do so and hopefully learned their lesson. Previous guidance was unattainable. Market cap has been chopped in 1/2
"Med-tech companies are built on quality products that health care professionals swear by, this loyalty takes time to build but once earned is rock solid compared to the next picture sharing app."
Agreed, they need to get insatalled base up and running. Number of units out there is enough. Just selling a unit that sits is counter productive.
I am building anotehr base at these levels. The mojo days of cantacut the cord pimping this prior to the secondary @ 14 last year are over. Its time for management to deliver.
MEDA sees massive jump in growth potential after global media agency selects Klarity as its preferred analytics and social monitoring platform
How high can MEDA climb after latest 20-language capability announced for Klarity? Analysts have set aggressive price targets as high as $2.30
I think the company is starting to learn the street games. They were naturally optimistic about their product and the street over-sold it so the players could make money. When the company couldn't deliver 50% quarterly growth the stock was punished. 20% quarterly revenue growth is ridiculous for a medical device company but is absolute #$%$ for a web company that measures growth in new users. I'll take 20% more revenue over 50% new users any day. The right way to market the company is to under promise and over delivery. Don't let the street or analyst over hype so they can get rich fast. Med-tech companies are built on quality products that health care professionals swear by, this loyalty takes time to build but once earned is rock solid compared to the next picture sharing app.
Yes. It is buying time! I too just loaded up several more thousand shares.
The market has no clue (yet) the impact of what the new testing processes will have when put on ONE chip. At that point not only will MORE optometrists and ophthalmologists sign on - it will make BIG inroads into nearly all medical offices. You have a test that is essentially NON-invasive and provides instant results.
What until after the analyst meeting next month - will look back at today and say "Dang! What a great opportunity to get in". And to make it even more fun the float has a lot of shorts which mean the squeeze starts!
Sentiment: Strong Buy
8/20/2014 Brock Wright Director Buy 23,000 $3.82 $87,860.00
8/19/2014 Brock Wright Director Buy 11,354 $3.83 $43,485.82
Bodes well for tearlab!
Sentiment: Strong Buy
With the 2 previous Alcon employees who were responsible for international sales on board; finally this market will be realized. International sales were 20 last Q and 5 the previous Q
Sentiment: Strong Buy